GEN Exclusives

More »

GEN News Highlights

More »
Aug 26, 2009

Phase III Trial with BioAlliance’s Orofacial Herpes Therapy Shows Positive Trend

  • BioAlliance Pharma reported positive preliminary results from a Phase III trial evaluating acyclovir Lauriad®, its mucooadhesive buccal tablet for the treatment of orofacial herpes. Compared with placebo, acyclovir Lauriad shortened the time from first prodromal symptoms to healing and reduced healing time for patients presenting with primary vesicular lesions.

    A higher percentage of patients in the acyclovir Lauriad group also demonstrated abortive lesions (i.e., without vesicular lesion). The single-dose, placebo-controlled trial included 722 patients with recurrent orofacial herpes.

    BioAlliance’s acyclovir Lauriad product is based on the same, patented mucoadhesive buccal tablet technology as Loramyc®, the company’s product for treating oropharyngeal candidiasis in immunocompromised patients. Loramyc has been approved in a number of European countries and just yesterday was sanctioned by the Swiss regulatory authorities. An FDA submission for Loramyc was also recently accepted.

    Bioalliance is developing three additional products using the Lauriad® technology. These include fentanyl Lauriad, clonidine Lauriad, and corticosteroid Lauriad. In its annual report for 2008 the company said clinical trials with the three products could start during 2009.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?